CLEMENT EFOBI: Open Payments
NPI 1952943037 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$718 in 34 payments from 10 companies in 2025. Trend: 2023 $390 · 2024 $165 · 2025 $718
Food & beverage: $718
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $229 |
| Supernus Pharmaceuticals, Inc. | 8 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| E.R. Squibb & Sons, L.L.C. | 3 | $75 |
| ABBVIE INC. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Novo Nordisk Inc | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| TMS NeuroHealth Centers Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
Products named: CAPLYTA, Qelbree, COBENFY, ABILIFY ASIMTUFII, REXULTI, VRAYLAR, Auvelity, ABILIFY MAINTENA.
Industry payments across DC — which companies pay providers there.
